Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Sernova Corp
T.SVA
Alternate Symbol(s):
SEOVF
Healthcare
Biotechnology
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch...
System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:SVA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(12)
•••
Ekenbullets
X
View Profile
View Bullboard History
Comment by
Ekenbullets
on May 04, 2023 1:53pm
RE:RE:Astrazeneca diabetes?
I have told you before I sell and buy this stock from time to time. I didnt hit the lows this time. Anyway seems there is still pleeeeenty of time to buy this at a low price for those who want. By
...more
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Comment by
BioTeck
on May 04, 2023 2:12am
RE:Astrazeneca diabetes?
Too bad you sold off at the low though. Hopefully you still have a few shares for the gamble.
Q Precious & Battery Metals to Drill Initial 1000 metres at La Corne and McKenzie East Gold Projects, Quebec
posted Apr 23, 2024 9:00am by
Q Precious & Battery Metals Corp
-
|
The Company is planning for an initial 1,000 metres of diamond drilling scheduled for mid- June 2024, with VMS targets on the La Corne South project at proposed depths ranging from 50 to 300 metres below surface as modelled by the EM survey and noted in historic drilling. TMC Geophysique completed deep-penetrating Pulse-EM -Time Domain Electromagnetic (TDEM) surveying on the claims that targeted ...read more
(12)
•••
Ekenbullets
X
View Profile
View Bullboard History
Post by
Ekenbullets
on May 03, 2023 12:08pm
Astrazeneca diabetes?
Good to see some risk reduction in Sernova stock. Would have been nice with a statement from Astrazenec in the press release... Good that AZ will do the discovery work at their facility, they wont
...more
(115)
•••
rixpix
X
View Profile
View Bullboard History
Post by
rixpix
on May 03, 2023 8:15am
SVA shares are up 25% in Germany!!
Volume is low but should pick up after the TSX opens.
(115)
•••
rixpix
X
View Profile
View Bullboard History
Comment by
rixpix
on May 03, 2023 8:03am
RE:New Press Release - Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
That's FKING GREAT news!!! AstraZeneca would not waste their time and money signing a collaboration with SVA if the cell pouch system had no value! I think this is fantastic!!! GLTA.
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 03, 2023 7:00am
New Press Release - Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
LONDON, Ontario, May 03, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of...
read article.
(72)
•••
bbowles
X
View Profile
View Bullboard History
Comment by
bbowles
on Apr 28, 2023 8:08pm
RE:RE:Good day for SVA today.
Not that Mrs Millar would be reading this bullboard. I would like to thank Mrs Millar, Dr. Steven Sangha and Mr. Bertram von Plettenberg for being concerned enough to spend their time
...more
(115)
•••
rixpix
X
View Profile
View Bullboard History
Comment by
rixpix
on Apr 28, 2023 11:38am
RE:Good day for SVA today.
Now that the clouds are starting to disperse over SVA headquarters i see blue skies ahead. Or should I say, green days ahead. Cheers.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 28, 2023 7:01am
New Press Release - Sernova Corp. Announces Voting Results of the 2023 Annual General Meeting of Shareholders
(TheNewswire)LONDON, Ontario – TheNewswire - April 28, 2023 - Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine company and leader in cell therapeutics focused on developing a potential ‘functional cure’ for type 1...
read article.
(115)
•••
rixpix
X
View Profile
View Bullboard History
Post by
rixpix
on Apr 27, 2023 5:54pm
Good day for SVA today.
With 2 new members voted onto the board things will no doubt get better.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 25, 2023 5:34pm
New Press Release - Concerned Shareholders of Sernova Corp. Wish to Thank All Shareholders
TORONTO, April 25, 2023 /CNW/ - The group of longstanding shareholders (the "Concerned Shareholders") of Sernova Corp (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) (XETRA: PSH) ("Sernova" or the "Company") wishes to thank all shareholders for their participation in electing the next Board of Directors.The...
read article.
(72)
•••
bbowles
X
View Profile
View Bullboard History
Comment by
bbowles
on Apr 24, 2023 11:57pm
RE:Just voted using the GOLD proxy forms
I did as well. Management must be concerned about the vote as I got a phone call reminding me to attend the meeting and vote for their directors.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 24, 2023 4:05pm
New Press Release - Successful Results Using Sernova's Cell Pouch System(TM) with Evotec's iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit
Evotec’s scalable GMP manufacturing process has been designed to produce induced pluripotent stem cell (iPSC)-derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and somatostatin (produced by alpha cells and delta cells, respectively), similar to...
read article.
(117)
•••
Tarbaby
X
View Profile
View Bullboard History
Post by
Tarbaby
on Apr 24, 2023 11:07am
TAkEOVER POTENTIAL
When will a takeover happen. Its inevitable at some time imo. Just WAY too cheap for its HUGE potential..!!
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover a Green Resources Stock Scoring Record Quarterly Growth
Stage Set for Creation of a Leading Intermediate Gold Producer
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study